Institution
University of Basel
Education•Basel, Basel-Stadt, Switzerland•
About: University of Basel is a education organization based out in Basel, Basel-Stadt, Switzerland. It is known for research contribution in the topics: Population & Transplantation. The organization has 25084 authors who have published 52975 publications receiving 2388002 citations. The organization is also known as: Universität Basel & Basel University.
Topics: Population, Transplantation, Gene, Poison control, Quantum dot
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A systematic review and meta-analysis finds that sanitation is associated with a reduced risk of transmission of helminthiases to humans.
Abstract: Background
In countries of high endemicity of the soil-transmitted helminth parasites Ascaris lumbricoides, Trichuris trichiura, and hookworm, preventive chemotherapy (i.e., repeated administration of anthelmintic drugs to at-risk populations) is the main strategy to control morbidity. However, rapid reinfection of humans occurs after successful deworming, and therefore effective preventive measures are required to achieve public health goals with optimal efficiency and sustainability.
504 citations
••
TL;DR: The intent is to provide a comprehensive overview of all work in the field up to December 2016, organized according to reaction class, which allows for comparison of similar reactions catalyzed by ArMs constructed using different metallocofactor anchoring strategies, cofactors, protein scaffolds, and mutagenesis strategies.
Abstract: The incorporation of a synthetic, catalytically competent metallocofactor into a protein scaffold to generate an artificial metalloenzyme (ArM) has been explored since the late 1970’s. Progress in the ensuing years was limited by the tools available for both organometallic synthesis and protein engineering. Advances in both of these areas, combined with increased appreciation of the potential benefits of combining attractive features of both homogeneous catalysis and enzymatic catalysis, led to a resurgence of interest in ArMs starting in the early 2000’s. Perhaps the most intriguing of potential ArM properties is their ability to endow homogeneous catalysts with a genetic memory. Indeed, incorporating a homogeneous catalyst into a genetically encoded scaffold offers the opportunity to improve ArM performance by directed evolution. This capability could, in turn, lead to improvements in ArM efficiency similar to those obtained for natural enzymes, providing systems suitable for practical applications and ...
504 citations
••
TL;DR: Methods are presented that estimate symmetrical and antisymmetrical optical aberrations, as well as magnification anisotropy, in a cryo-EM data set, and considering these effects improves the resolution of the 3D reconstruction when these effects are present.
504 citations
••
TL;DR: An algorithm is described for calculation of stability constants and absorption spectra, together with the associated standard errors, at a reasonable expense of computer time.
503 citations
••
University of Basel1, Vita-Salute San Raffaele University2, University of Maryland, Baltimore3, McGill University4, Neurocrine Biosciences5, Stanford University6, Valley Hospital7, Yale University8, Sapienza University of Rome9, Aix-Marseille University10, Ruhr University Bochum11, Centre Hospitalier Universitaire de Toulouse12, Université de Montréal13, Montreal Neurological Institute and Hospital14
TL;DR: There were no increases in either clinical relapses or in new enhancing lesions in any patient, even those with hypersensitivity reactions, and secondary analysis showed that the volume and number of enhancing lesions were reduced at a dose of 5 mg.
Abstract: In this ‘double-blind’, randomized, placebo-controlled phase II trial, we compared an altered peptide ligand of myelin basic protein with placebo, evaluating their safety and influence on magnetic resonance imaging in relapsing–remitting multiple sclerosis. A safety board suspended the trial because of hypersensitivity reactions in 9% of the patients. There were no increases in either clinical relapses or in new enhancing lesions in any patient, even those with hypersensitivity reactions. Secondary analysis of those patients completing the study showed that the volume and number of enhancing lesions were reduced at a dose of 5 mg. There was also a regulatory type 2 T helper-cell response to altered peptide ligand that cross-reacted with the native peptide.
503 citations
Authors
Showing all 25374 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yang Yang | 171 | 2644 | 153049 |
Martin Karplus | 163 | 831 | 138492 |
Frank J. Gonzalez | 160 | 1144 | 96971 |
Paul Emery | 158 | 1314 | 121293 |
Matthias Egger | 152 | 901 | 184176 |
Don W. Cleveland | 152 | 444 | 84737 |
Ashok Kumar | 151 | 5654 | 164086 |
Kurt Wüthrich | 143 | 739 | 103253 |
Thomas J. Smith | 140 | 1775 | 113919 |
Robert Huber | 139 | 671 | 73557 |
Peter Robmann | 135 | 1438 | 97569 |
Ernst Detlef Schulze | 133 | 670 | 69504 |
Michael Levine | 129 | 586 | 55963 |
Claudio Santoni | 129 | 1027 | 80598 |
Pablo Garcia-Abia | 126 | 989 | 78690 |